Compare WLDN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | SLN |
|---|---|---|
| Founded | 1964 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2006 | 2010 |
| Metric | WLDN | SLN |
|---|---|---|
| Price | $70.15 | $19.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $117.50 | $19.75 |
| AVG Volume (30 Days) | 199.9K | ★ 4.4M |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.89 | N/A |
| Revenue | ★ $273,352,000.00 | $559,000.00 |
| Revenue This Year | $21.31 | N/A |
| Revenue Next Year | $16.11 | $131.31 |
| P/E Ratio | $23.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $61.51 | $4.19 |
| 52 Week High | $137.00 | $19.87 |
| Indicator | WLDN | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 78.21 |
| Support Level | $65.92 | $13.01 |
| Resistance Level | $86.52 | $19.87 |
| Average True Range (ATR) | 3.84 | 0.07 |
| MACD | -0.30 | -0.04 |
| Stochastic Oscillator | 45.37 | 58.49 |
Willdan Group Inc is a technical services company focused on energy and infrastructure solutions. The company's solutions include energy planning and analytics, consulting, software, public finance, engineering, and program implementation. It operates through two segments: i) Energy segment: It provides specialized, comprehensive energy solutions to businesses, utilities, state agencies, municipalities, and non-profit organizations. ii) Engineering & Consulting: It provides civil engineering and construction management, building and safety services, city engineering and planning support, civil design, geotechnical services, and material testing. The majority of revenue is derived from the Energy segment. Geographically, all of the company's revenue is generated from the United States.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.